The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.
A user is using Fluridil for hair loss and is concerned that styling clay and powder might affect the absorption of the treatment. They apply clay in the morning and Fluridil in the evening and are considering switching to a styling powder.
The small soft-gel capsule inside Duodart contains dutasteride, and the powder/beads contain tamsulosin. You can open the large capsule and take only the dutasteride soft-gel.
The conversation is about finding affordable tretinoin with UK delivery options. Users discuss a finasteride, minoxidil, and tretinoin spray from e-surgery and suggest other sources like Zing meds and Skinorac.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
A user with diffuse thinning shares a tip for improving hair appearance by using a shea butter and coconut oil serum from Trader Joe's at night. They are on finasteride and considering adding minoxidil for better results.
Dutasteride and finasteride mesotherapy may have fewer side effects like erectile dysfunction and libido loss compared to oral treatments, but it's less effective and more costly. Few people discuss it, and experiences with mesotherapy are limited.
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
The conversation discusses obtaining an online EU prescription for Bimatoprost/Lumigan for hair loss without an in-person doctor visit. The user is seeking alternatives to physical consultations for this treatment.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.
Latanoprost for hair loss is available in Canada at Ford's Family Pharmacy in New Brunswick, with up to 0.03% concentration, six times stronger than glaucoma medication Xalatan.
PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
The conversation is about skepticism towards a hair serum advertised on Instagram, with users doubting its effectiveness and one sharing a personal negative experience with the product.
The conversation discusses obtaining oral minoxidil from countries like India or Thailand or by ordering powder from China to make capsules. The user seeks advice on sourcing and creating their own capsules due to unavailability in their country.
Dutasteride capsules were exposed to heat and humidity, causing them to soften, and the user considered replacing them with new ones from a local pharmacy. Suggestions included alternating between old and new capsules, storing them properly, and using them topically with Minoxidil, though the user decided to wait and see the effects of Dutasteride first.
Hair therapy advertisements claim to use a mix of fallopia multiflora, ginseng, angelica sinensis, and vitex rotundifolia for hair growth. A user dismisses it as fake.